Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA -
Panminerva Med. 2018 Dec;60(4):174-184. doi: 10.23736/S0031-0808.18.03542-5. Epub 2018 Oct 5.
Despite significant progress in our understanding and the development of novel therapies, most patients with multiple myeloma will experience relapse of their disease. Therapy of relapsed myeloma has improved due to the availability of novel agents that are highly active against the disease. However, the selection of therapy can be challenging due to the emergence of toxicities, comorbidities and frailty. In the following we discuss our approach to the treatment of the patient with relapsed myeloma.
尽管我们在理解和开发新疗法方面取得了重大进展，但大多数多发性骨髓瘤患者仍会经历疾病复发。由于新型药物对该疾病具有高度活性，复发性骨髓瘤的治疗得到了改善。然而，由于毒性、合并症和虚弱的出现，治疗的选择可能具有挑战性。在下面，我们讨论了我们对复发性骨髓瘤患者的治疗方法。
